Christelle Huguet | Ipsen Leadership
Skip to main content
Ipsen Home Page
Press shift tab to select search category

Loading...
  • Media  arrow down
    < Back
    • Press Releases
    • Media Statements
    • Media Library
    • Our 2023 Integrated Annual Report is live!

      Featured Image
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • Financial Results
    • Annual Reports and Accounts
    • Corporate News
    • Financial Calendar
    • Investor Events
    • Shareholder Information
    • Regulated Information
    • Key Contacts
  • Partnering
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
  • Press shift tab to select search category

    Loading...
  • English  EN     Français  FR     EN  arrow_down
    • English EN
    • Français FR
  • Global Global
    < Back
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • United States
    • Brazil
    • Canada
    • Mexico
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Switzerland
    • Austria
  • Home
  • Companyarrow down
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Sciencearrow down
      < Back
    • Science
    • Science
    • Oncology
    • Rare Disease
    • Neuroscience
    • Products
    • R&D
    • Pipeline
    • Clinical Trials
    • Lay Summaries
  • Sustainabilityarrow down
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patientsarrow down
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories
  1. Home
  2. Company
  3. Leadership
  4. Christelle Huguet

Christelle Huguet

Back
Christelle Huguet

Christelle Huguet

  • Executive Vice President,
  • Head of R&D
  • Follow in LinkedIn

Christelle was appointed Executive Vice President, R&D at Ipsen in September 2023.

Christelle is responsible for discovery to late-stage development programs across our three Therapeutic Areas of Oncology, Rare Disease and Neuroscience, in addition to leading Ipsen’s External Innovation strategy. Christelle joined Ipsen in May 2020 as Head of Research, External Innovation and Early Development where she drove the expansion of our early development and clinical portfolio in addition to overseeing all early development programs to accelerate innovation.

Previously, Christelle served as Chief Scientific Officer of X-Chem, moving from Alexion Pharmaceuticals where she was Head of Internal Research focussing on Rare Diseases. Prior to this Christelle held a variety of leadership roles at Pfizer specializing in drug discovery and development across multiple therapeutic areas including Immunology & Inflammation, Respiratory, Women’s Health and Gastro-intestinal.

Christelle received a PhD in Molecular and cellular Biology at the Pasteur Institute.

Related stories

A Life in Science: The Privilege of Making a Difference 
03 March 2025 1 mins read

A Life in Science: The Privilege of Making a Difference 

Improving Diversity in Research and Development to Drive Health Equity
20 May 2024 4 mins read

Improving Diversity in Research and Development to Drive Health Equity

FY 2023 results announcement 
08 February 2024 0 mins read

FY 2023 results announcement 

Capital Markets Day 2023
03 November 2023 0 mins read

Capital Markets Day 2023

IPN price

€102.40

 €-1.30 (-1.25%)

  • Media
  • Investors
  • Partnering
  • Careers
  • Company
  • Sustainability
  • Patients
  • Stories
  • Annual Report
  • Contact us

Latest_Ipsen logo
LinkedIn Facebook Instagram Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

© Ipsen Pharma. All rights reserved - 2025

You are now leaving the Ipsen group website. To continue, please click on Continue?

Continue